Essex Bio-Technology Reports Robust Results for FY2025, Turnover Soars 8.6% to HK$1814 million, Net Profit up 3.5% to HK$ 318.1 million, Total Dividend Increases by 16.7% to HK14 Cents per Share

Flagship Beifushu and Beifuji Series Drive Growth, Expansion into Singapore and Strategic Partnerships Fuel Diversification

Mar. 23, 2026 at 8:51pm

Got story updates? Submit your updates here. ›

Essex Bio-Technology Limited, a leading biologic group that develops, manufactures and commercialises genetically engineered therapeutic recombinant bovine basic fibroblast growth factor, reported robust annual results for 2025 with revenue up 8.6% to HK$1,813.8 million and net profit up 3.5% to HK$318.1 million. The group achieved multiple regulatory milestones, expanded its product portfolio through strategic collaborations, and marked the landmark entry of its flagship Beifushu product into Singapore, underscoring its commitment to innovation and operational excellence.

Why it matters

Essex Bio-Technology's strong financial performance and diversification efforts demonstrate its ability to drive sustained growth in China's rapidly evolving biopharmaceutical market. The group's focus on innovation, strategic partnerships, and international expansion positions it well to capitalize on emerging opportunities and solidify its leadership in the ophthalmology, surgical, and healthcare segments.

The details

Essex Bio-Technology's revenue growth was fueled by its flagship Beifushu and Beifuji product series, which contributed 83.5% of turnover. The ophthalmology segment grew 8.2% year-on-year, led by Beifushu unit-dose eye drops, while the surgical segment rose 1.8% supported by Beifuji's broad clinical applications. The group also saw significant growth in its healthcare and partner services business, up 350% year-on-year. Essex maintained a healthy financial position with HK$782.7 million in cash and cash equivalents and proposed a 16.7% increase in total dividend to HK14 cents per share.

  • Essex Bio-Technology reported its robust annual results for the year ended 31st December 2025.
  • The group obtained NMPA approval for multi-dose Diquafosol Sodium Eye Drops in July 2025 and multi-dose Sodium Hyaluronate Eye Drops in January 2026.
  • Essex's Bevacizumab ophthalmic injection BLA was accepted by NMPA in August 2025.

The players

Essex Bio-Technology Limited

A leading biologic group that develops, manufactures and commercialises genetically engineered therapeutic recombinant bovine basic fibroblast growth factor.

Beifushu

Essex Bio-Technology's flagship ophthalmic product series.

Beifuji

Essex Bio-Technology's flagship wound healing product series.

Kenvue

A global consumer health leader that Essex Bio-Technology partnered with to promote and market select consumer health products in China.

Osteopore

A company whose innovative dental, orthodontic and maxillofacial products Essex Bio-Technology obtained exclusive distribution rights for in China, Hong Kong and Macau.

Got photos? Submit your photos here. ›

What they’re saying

“2025 was a standout year with Beifushu's landmark entry into Singapore, driving robust growth through flagship products, innovation-focused R&D, and strategic partnerships. Essex remains committed to addressing unmet needs and driving long-term growth.”

— Patrick Ngiam, Chairman of Essex Bio-Technology

What’s next

Essex Bio-Technology's second factory at Zhuhai Hi-Tech Industrial Park, with a gross floor area of about 58,000 square meters for R&D, manufacturing, office and dormitory, is expected to complete in the period of 2026 -2027.

The takeaway

Essex Bio-Technology's robust financial performance, regulatory milestones, strategic partnerships, and international expansion demonstrate its ability to innovate and diversify its business to capitalize on growth opportunities in China's dynamic biopharmaceutical market. The group's commitment to addressing unmet medical needs and delivering shareholder value positions it well for continued success.